---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036410"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T08:09:43.423194+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kyverna reports FY 2023 net loss of $60.4M; IPO raised $366.9M in Feb 2024

## Summary
- Net loss $60.4M ($89.61/share) vs. $28.9M ($63.43/share) in FY 2022; cash burn $52.4M in operating activities.
- Cash, equivalents and marketable securities $57.5M as of Dec 31, 2023; Feb 2024 IPO gross proceeds ~$366.9M.
- Treated 14 autoimmune patients with KYV-101 CAR T therapy; FDA cleared Phase 2 trials in MS, MG and Phase 1/2 in systemic sclerosis.
- Received FDA Fast Track Designations for KYV-101 in refractory MG, refractory progressive MS, and lupus nephritis.
- Upcoming data releases at EULAR (Q2 2024), ECTRIMS (Q3 2024) and ACR (Q4 2024) for KYV-101.

## SEC filing metadata
- accession: 0000950170-24-036410
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000095017024036410/0000950170-24-036410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000095017024036410/8k_for_earnings_release_.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036410
- JSON: https://secwatch.observer/filing/0000950170-24-036410.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036410.txt

## Key facts
- Earnings Releases
  Kyverna Therapeutics, Inc. reported the full year ended December 31, 2023 results: net income net loss of $60.4 million, or a net loss per common share of $89.61, EPS net loss per common share of $89.61.
  - Period: the full year ended December 31, 2023
  - Net income: net loss of $60.4 million, or a net loss per common share of $89.61
  - EPS: net loss per common share of $89.61
  - Result: reported results
  source text: For the year ended December 31, 2023, the company reported a net loss of $60.4 million, or a net loss per common share of $89.61, compared to a net loss of $28.9 million, or a net loss per common share of $63.43, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1994702/000095017024036410/0000950170-24-036410-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.